Thiosemicarbazones are organic compounds resulting from the condensation of thiosemicarbazide with a carbonyl group, characterized by the presence of a -NH-CS-NH-CO- functional structure and widely used in chelation therapy due to their ability to form stable complexes with various metal ions.
Separation systems containing a relatively long-lived parent radionuclide which produces a short-lived daughter in its decay scheme. The daughter can be periodically extracted (milked) by means of an appropriate eluting agent.
Unstable isotopes of copper that decay or disintegrate emitting radiation. Cu atoms with atomic weights 58-62, 64, and 66-68 are radioactive copper isotopes.
A class of compounds of the type R-M, where a C atom is joined directly to any other element except H, C, N, O, F, Cl, Br, I, or At. (Grant & Hackh's Chemical Dictionary, 5th ed)
An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals.

Different foci for the regulation of the activity of the KefB and KefC glutathione-gated K+ efflux systems. (1/364)

KefB and KefC are glutathione-gated K+ efflux systems in Escherichia coli, and the proteins exhibit strong similarity at the level of both primary sequence and domain organization. The proteins are maintained closed by glutathione and are activated by binding of adducts formed between glutathione and electrophiles. By construction of equivalent mutations in each protein, this study has analyzed the control over inactive state of the proteins. A UV-induced mutation in KefB, L75S, causes rapid spontaneous K+ efflux but has only a minor effect on K+ efflux via KefC. Similarly amino acid substitutions that cause increased spontaneous activity in KefC have only small effects in KefB. Exchange of an eight amino acid region from KefC (HALESDIE) with the equivalent sequence from KefB (HELETAID) has identified a role for a group of acidic residues in controlling KefC activity. The mutations HELETAID and L74S in KefC act synergistically, and the activity of the resultant protein resembles that of KefB. We conclude that, despite the high degree of sequence similarity, KefB and KefC exhibit different sensitivities to the same site-specific mutations.  (+info)

Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. (2/364)

Methylglyoxal (MG), an endogenous metabolite that increases in diabetes and is a common intermediate in the Maillard reaction (glycation), reacts with proteins and forms advanced glycation end products. In the present study, we identify a novel MG-arginine adduct and also characterize the structure of a major fluorescent adduct. In addition, we describe the immunochemical study on the MG-arginine adducts using monoclonal antibody directed to MG-modified protein. Upon incubation of Nalpha-acetyl-L-arginine with MG at 37 degrees C, two nonfluorescent products and one fluorescent product were detected as the major products. The nonfluorescent products were identified as the Ndelta-(5-hydro-5-methyl-4-imidazolon-2-yl)-L-ornithine derivatives (5-hydro-5-methylimidazolone) and a novel MG-arginine adduct having a tetrahydropyrimidine moiety (Ndelta-(4-carboxy-4,6-dimethyl-5, 6-dihydroxy-1,4,5,6-tetrahydropyrimidine-2-yl)-L-ornithine). On the basis of the following chemical and spectroscopic evidence, the major fluorescent product, putatively identified as Ndelta-(5-methylimidazolon-2-yl)-L-ornithine (5-methylimidazolone), was found to be identical to Ndelta-(5-hydroxy-4, 6-dimethylpyrimidine-2-yl)-L-ornithine (argpyrimidine): (i) the low and high resolution fast atom bombardment-mass spectrometry gave a molecular ion peak at m/z of 297 (M+H) and a molecular formula of C10H25O6N4, respectively, which coincided with argpyrimidine; (ii) the 1H NMR spectrum of this product in d6-Me2SO showed a singlet at 2.10 ppm corresponding to six protons; (iii) the peak corresponding to the 5-methylimidazolone derivative was not detected by the liquid chromatography-mass spectrometry with the mode of selected ion monitoring; (iv) incubation of 5-hydro-5-methylimidazolone, a putative precursor of 5-methylimidazolone, at 37 degrees C for 14 days scarcely generated 5-methylimidazolone. On the other hand, as an immunochemical approach to the detection of these MG adducts, we raised the monoclonal antibodies (mAb3C and mAb6B) directed to the MG-modified protein and found that they specifically recognized the major fluorescent product, argpyrimidine, as the dominant epitope. The immunohistochemical analysis of the kidneys from diabetic patients revealed the localization of argpyrimidine in intima and media of small artery walls. Furthermore, the accumulation of argpyrimidine was also observed in some arterial walls of the rat brain after middle cerebral artery occlusion followed by reperfusion. These results suggest that argpyrimidine may contribute to the progression of not only long term diabetic complications, such as nephropathy and atherosclerosis, but also the tissue injury caused by ischemia/reperfusion.  (+info)

Energetics of the proposed rate-determining step of the glyoxalase I reaction. (3/364)

The proposed rate-limiting step of the reaction catalyzed by glyoxalase I is the proton abstraction from the C1 carbon atom of the substrate by a glutamate residue, resulting in a high-energy enolate intermediate. This proton transfer reaction was modelled using molecular dynamics and free energy perturbation simulations, with the empirical valence bond method describing the potential energy surface of the system. The calculated rate constant for the reaction is approximately 300-1500 s(-1) with Zn2+, Mg2+ or Ca2+ bound to the active site, which agrees well with observed kinetics of the enzyme. Furthermore, the results imply that the origin of the catalytic rate enhancement is mainly associated with enolate stabilization by the metal ion.  (+info)

Simultaneous determination of formaldehyde and methylglyoxal in urine: involvement of semicarbazide-sensitive amine oxidase-mediated deamination in diabetic complications. (4/364)

The deamination of methylamine and aminoacetone by semicarbazide-sensitive amine oxidase (SSAO) produces formaldehyde and methylglyoxal, respectively, which have been presumed to be involved in diabetic complications. A high-performance liquid chromatography procedure using 2,4-dinitrophenylhydrazine (DNPH) as a derivatizing agent is developed to determine endogenous formaldehyde, methylglyoxal, malondialdehyde, and acetaldehyde. The devised DNPH method is sensitive enough to analyze aldehyde levels in urine. An increase in the excretion of formaldehyde, methylglyoxal, and malondialdehyde is confirmed in streptozotocin-induced diabetic rats. Following the chronic administration of methylamine, the urinary levels of both formaldehyde and malondialdehyde (a product from lipid peroxidation) are found to be substantially increased. A potent selective SSAO inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine hydrochloride (MDL-72974A), reduced the formation of formaldehyde, methylglyoxal, and malondialdehyde. The increase of the cytotoxic aldehyde levels as a result of increased SSAO-mediated deamination may occur in some pathological conditions.  (+info)

Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids. (5/364)

OBJECTIVE: To study the presence of 1,2-dicarbonyl compounds in peritoneal dialysis (PD) fluids, their concentration in effluents with increasing dwell time, and their role in the formation of advanced glycation end-products (AGEs). MEASUREMENTS: Dicarbonyl compounds in heat- and filter-sterilized PD fluids were quantified by reverse-phase high performance liquid chromatography (HPLC) after derivatization to dimethoxyquinoxaline derivatives. Kinetics of the in vitro formation of AGEs upon incubation of 1,2-dicarbonyl compounds or PD fluids with albumin, with or without aminoguanidine, were measured by AGE fluorescence (excitation/emission wavelengths of 350 nm/430 nm). PATIENTS: AGEs and dicarbonyl compounds were measured in effluents collected from standardized 4-hour dwells from 8 continuous cycling peritoneal dialysis patients. RESULTS: In PD fluids, 3-deoxyglucosone (3-DG) has been identified as the major dicarbonyl compound formed during the process of heat sterilization. The process also formed glyoxal (GO) and methylglyoxal (MGO), with the amount of 3-DG being approximately 25-60 times higher than GO and MGO. When incubated with albumin, the identified 1,2-dicarbonyl compounds rapidly formed AGEs. The formation of AGEs was more pronounced in conventional heat-sterilized PD fluids compared with filter-sterilized PD fluids, and was completely inhibited by aminoguanidine. In effluents, the concentration of MGO, GO, and 3-DG decreased with increasing dwell time, with a concomitant increase in AGE fluorescence. CONCLUSIONS: The dicarbonyl compounds 3-DG, MGO, and GO are potent promoters of AGE formation. The presence of these and possibly other dicarbonyl compounds formed during heat sterilization of glucose-based PD fluids is, to a large extent, responsible for the in vitroAGE formation by these fluids, as evidenced by the speed of AGE formation in PD fluids and the complete inhibition by aminoguanidine. Because 3-DG, MGO, and GO are rapidly cleared from PD fluids during dialysis, these compounds may contribute to the in vivo AGE formation in PD patients.  (+info)

Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. (6/364)

The glycation of proteins by glucose has been linked to the development of diabetic complications and other diseases. Early glycation is thought to involve the reaction of glucose with N-terminal and lysyl side chain amino groups to form Schiff's base and fructosamine adducts. The formation of the alpha-oxoaldehydes, glyoxal, methylglyoxal and 3-deoxyglucosone, in early glycation was investigated. Glucose (50 mM) degraded slowly at pH 7.4 and 37 degrees C to form glyoxal, methylglyoxal and 3-deoxyglucosone throughout a 3-week incubation period. Addition of t-BOC-lysine and human serum albumin increased the rate of formation of alpha-oxoaldehydes - except glyoxal and methylglyoxal concentrations were low with albumin, as expected from the high reactivity of glyoxal and methylglyoxal with arginine residues. The degradation of fructosyl-lysine also formed glyoxal, methylglyoxal and 3-deoxyglucosone. alpha-Oxoaldehyde formation was dependent on the concentration of phosphate buffer and availability of trace metal ions. This suggests that alpha-oxoaldehydes were formed in early glycation from the degradation of glucose and Schiff's base adduct. Since alpha-oxoaldehydes are important precursors of advanced glycation adducts, these adducts may be formed from early and advanced glycation processes. Short periods of hyperglycaemia, as occur in impaired glucose tolerance, may be sufficient to increase the concentrations of alpha-oxoaldehydes in vivo.  (+info)

Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. (7/364)

Peritoneal membrane permeability deteriorates in peritoneal dialysis (PD) patients. We test whether glucose degradation products (GDPs) in PD fluids, glyoxal, methylglyoxal and 3-deoxyglucosone, stimulate the production of vascular endothelial growth factor (VEGF), a factor known to enhance vascular permeability and angiogenesis. VEGF increased in cultured rat mesothelial and human endothelial cells exposed to methylglyoxal, but not to glyoxal or 3-deoxyglucosone. VEGF also increased in peritoneal tissue of rats given intraperitoneally methylglyoxal. VEGF and carboxymethyllysine (CML) (formed from GDPs) co-localized immunohistochemically in mesothelial layer and vascular walls of the peritoneal membrane of patients given chronic PD. By contrast, in the peritoneum of non-uremic subjects, VEGF was identified only in vascular walls, in the absence of CML. VEGF production induced by GDPs may play a role in the progressive deterioration of the peritoneal membrane.  (+info)

Glutathione is involved in environmental stress responses in Rhizobium tropici, including acid tolerance. (8/364)

The isolation of rhizobial strains which exhibit an intrinsic tolerance to acidic conditions has been reported and has facilitated studies on the basic mechanisms underlying acid tolerance. Rhizobium tropici strain CIAT899 displays a high intrinsic tolerance to acidity and therefore was used in this work to study the molecular basis of bacterial responses to acid conditions and other environmental stresses. We generated a collection of R. tropici CIAT899 mutants affected in acid tolerance using Tn5-luxAB mutagenesis, and one mutant strain (CIAT899-13T2), which fails to grow under acid conditions, was characterized in detail. Strain CIAT899-13T2 was found to contain a single Tn5-luxAB insertion in a gene showing a high degree of similarity with the Escherichia coli gshB gene, encoding the enzyme glutathione synthetase. Intracellular potassium pools and intracellular pH levels were found to be lower in the mutant than in the parent. The glutathione-deficient mutant was shown to be sensitive to weak organic acids, osmotic and oxidative stresses, and the presence of methylglyoxal. Glutathione restores responses to these stresses almost to wild-type levels. Our data show that in R. tropici the production of glutathione is essential for growth in extreme environmental conditions. The mutant strain CIAT899-13T2 induced effective nodules; however, it was found to be outcompeted by the wild-type strain in coinoculation experiments.  (+info)

Thiosemicarbazones are a class of organic compounds that contain the functional group R-NH-CS-N=CNR', where R and R' are organic radicals. These compounds have been widely studied due to their various biological activities, including antiviral, antibacterial, and anticancer properties. They can form complexes with metal ions, which can also exhibit interesting biological activity. Thiosemicarbazones have the ability to act as chelating agents, forming stable coordination compounds with many metal ions. This property has been exploited in the development of new drugs and diagnostic agents.

Radionuclide generators, also known as "radiogenic sources" or "generator systems," are devices that contain a parent radionuclide that decays into a daughter radionuclide. The parent nuclide has a longer half-life than the daughter nuclide and remains within the generator system, while the daughter nuclide is produced continuously through the decay process and can be extracted for use in medical imaging or therapeutic procedures.

The most common type of radionuclide generator used in nuclear medicine is the technetium-99m (^99m Tc) generator, which contains molybdenum-99 (^99 Mo) as the parent nuclide. Molybdenum-99 has a half-life of 66 hours and decays into technetium-99m, which has a half-life of only 6 hours. Technetium-99m emits gamma rays that can be detected by gamma cameras, making it useful for a wide range of diagnostic procedures such as bone scans, lung perfusion imaging, and myocardial perfusion imaging.

Radionuclide generators are typically used in hospitals and medical centers where they can provide a convenient and cost-effective way to produce small quantities of radionuclides for diagnostic or therapeutic purposes. The extracted daughter nuclide can be used immediately, reducing the need for complex shipping and handling procedures associated with other radioactive materials.

Copper radioisotopes are radioactive isotopes or variants of the chemical element copper. These isotopes have an unstable nucleus and emit radiation as they decay over time. Copper has several radioisotopes, including copper-64, copper-67, and copper-60, among others. These radioisotopes are used in various medical applications such as diagnostic imaging, therapy, and research. For example, copper-64 is used in positron emission tomography (PET) scans to help diagnose diseases like cancer, while copper-67 is used in targeted radionuclide therapy for cancer treatment. The use of radioisotopes in medicine requires careful handling and regulation due to their radiation hazards.

Organometallic compounds are a type of chemical compound that contain at least one metal-carbon bond. This means that the metal is directly attached to carbon atom(s) from an organic molecule. These compounds can be synthesized through various methods, and they have found widespread use in industrial and medicinal applications, including catalysis, polymerization, and pharmaceuticals.

It's worth noting that while organometallic compounds contain metal-carbon bonds, not all compounds with metal-carbon bonds are considered organometallic. For example, in classical inorganic chemistry, simple salts of metal carbonyls (M(CO)n) are not typically classified as organometallic, but rather as metal carbonyl complexes. The distinction between these classes of compounds can sometimes be subtle and is a matter of ongoing debate among chemists.

I'm sorry for any confusion, but "Pyruvaldehyde" is not a recognized term in medical or clinical sciences. It is, however, a chemical compound with the formula CH3COCHO, which is sometimes used in laboratory research. It might be referred to in the context of biochemistry or pathophysiology of certain diseases, but it's not a term commonly used in medical diagnosis or treatment. Always consult with a healthcare professional or trusted medical source for information related to health and medicine.

Robert Shapiro; Bertram I. Cohen; Shian-Jan Shiuey; Hans Maurer (1969). "Reaction of guanine with glyoxal, pyruvaldehyde, and ...
Simultaneous determination of lead and copper by carbon paste electrodes modified with pyruvaldehyde bis (NN-dibutyl ...
Morales-Berstein, F., Biessy, C., Viallon, V., Goncalves-Soares, A., Casagrande, C., Hémon, B., Kliemann, N., Cairat, M., Blanco Lopez, J., Al Nahas, A., Chang, K., Vamos, E., Rauber, F., Bertazzi Levy, R., Barbosa Cunha, D., Jakszyn, P., Ferrari, P., Vineis, P., Masala, G., Catalano, A., & 29 othersSonestedt, E., Borné, Y., Katzke, V., Bajracharya, R., Agnoli, C., Guevara, M., Heath, A., Radoï, L., Mancini, F., Weiderpass, E., Huerta, J. M., Sánchez, M-J., Tjønneland, A., Kyrø, C., Schulze, M. B., Skeie, G., Lukic, M., Braaten, T., Gunter, M., Millett, C., Agudo, A., Brennan, P., Borges, M. C., Richmond, R. C., Richardson, T. G., Davey Smith, G., Relton, C. L., Huybrechts, I. & EPIC Network, 2023 Nov 22, (E-pub ahead of print) In: European Journal of Nutrition.. Research output: Contribution to journal › Article › peer-review ...
Hsu, W-H., Lee, B-H. & Pan, T-M., 2012, The ISEKI (Integrating Food Science and Engineering Knowledge Into the Food Chain)-Food Association (IFA). Palmerston North, New Zealand. Research output: Chapter in Book/Report/Conference proceeding › Conference contribution ...
722KLD7415 (Pyruvaldehyde). GAN16C9B8O (Glutathione). Entry Date(s): Date Created: 20220412 Date Completed: 20220413 Latest ...
Powered by Pure, Scopus & Elsevier Fingerprint Engine™ © 2023 Elsevier B.V. We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the use of cookies. ...
Araki, Y., Asano, N., Yamamoto, N., Hayashi, K., Takeuchi, A., Miwa, S., Igarashi, K., Higuchi, T., Kensaku, A. B. E., Taniguchi, Y., Yonezawa, H., Morinaga, S., Asano, Y., Yoshida, T., Hanayama, R., Matsuzaki, J., Ochiya, T., Kawai, A. & Tsuchiya, H., 2023 Jun, In: Oncology Letters. 25, 6, 222.. Research output: Contribution to journal › Article › peer-review ...
由 Pure、Scopus 與 Elsevier Fingerprint Engine™ © 2023 Elsevier B.V. 提供技術支援 我們使用 Cookie 來協助提供並增強我們的服務並量
Thompson, G. R., Le, T., Chindamporn, A., Kauffman, C. A., Alastruey-Izquierdo, A., Ampel, N. M., Andes, D. R., Armstrong-James, D., Ayanlowo, O., Baddley, J. W., Barker, B. M., Lopes Bezerra, L., Buitrago, M. J., Chamani-Tabriz, L., Chan, J. F. W., Chayakulkeeree, M., Cornely, O. A., Cunwei, C., Gangneux, J. P., Govender, N. P., & 19 othersHagen, F., Hedayati, M. T., Hohl, T. M., Jouvion, G., Kenyon, C., Kibbler, C. C., Klimko, N., Kong, D. C. M., Krause, R., Lee Lee, L., Meintjes, G., Miceli, M. H., Rath, P. M., Spec, A., Queiroz-Telles, F., Variava, E., Verweij, P. E., Schwartz, I. S. & Pasqualotto, A. C., Dec 2021, In: The Lancet Infectious Diseases. 21, 12, p. e364-e374. Research output: Contribution to journal › Review article › peer-review ...
Dive into the research topics of Effect of Cannabidiol on the Neural Glyoxalase Pathway Function and Longevity of Several C. elegans Strains Including a C. elegans Alzheimers Disease Model. Together they form a unique fingerprint. ...
Pyruvaldehyde Medicine & Life Sciences 100% * Methylglyoxal Chemical Compounds 94% * Bromides Medicine & Life Sciences 89% ...
Pyruvaldehyde Medicine & Life Sciences 84% * Methylglyoxal Chemical Compounds 80% View full fingerprint ...
Pyruvaldehyde Medicine & Life Sciences 39% * Proximal Kidney Tubule Medicine & Life Sciences 35% ...
Pyruvaldehyde. NAD. NADH. H. 2. O. L-2-Amino-3-. oxobutanoic. acid. CO. 2. Acetyl-CoA. Glycine. CoA. Dimethylglycine. H. 2. O. ...
Pyruvaldehyde. NAD. NADH. H. 2. O. L-2-Amino-3-oxobutanoic acid. CO. 2. Acetyl-CoA. Glycine. CoA. Accumulation. Dimethylglycine ...
Cu-64 PTSM (Pyruvaldehyde-bis(N4-methylthiosemicarbazone)): Employed in brain perfusion studies and hypoxia imaging in tumours ...
Our Chemicals such as glyoxylic acid, glyoxal, Chloroacetone, Phenoxyethanol, Pyruvaldehyde etc. Cangzhou, China ...
Simillarly2- Methyl Quinoxaline has been prepared by the reaction of o-phenyldiamine and pyruvaldehyde. ...
FORMATION OF THE THIOESTER, N-ACETYL, S-LACTOYLCYSTEINE, BY REACTION OF N-ACETYLCYSTEINE WITH PYRUVALDEHYDE IN AQUEOUS SOLUTION ...
... but exfoliated materials gave higher yields of methyl lactate and pyruvaldehyde dimethyl acetal than their respective layered ...
PURPOSE: The [64Cu]Cu-PTSM radiopharmaceutical, pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(II), is suitable for use ...
Our Chemicals such as glyoxylic acid, glyoxal, Chloroacetone,Phenoxyethanol, Glycolic acid, Pyruvaldehyde, allantoin, 2- ...
Sperm Dna-ferrous Fumarate-folic Acid-fumaric Acid-kali Aspartate-mang Phos-mang Gluconate-mang Phos Ii-pyruvaldehyde-nat ...
Copper-64-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for the Prevention of Tumor Growth at Wound Sites following ...
A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC ...
Text; Format: print Publication details: Rome : Food and Agriculture Organization, 1989Other title: Utilisation des aliments tropicaux : sucres, épices et stimulants , Utilizacion de alimentos tropicales : azucar, especias y estimulantes.Availability: Items available for loan: WHO HQ (3)Call number: WA 695 89UT-4, ... ...
Oxopropanal use Pyruvaldehyde Oxoquinolines use Quinolones Oxosteroids use Ketosteroids Oxosuccinates use Oxaloacetates ...
Oxopropanal use Pyruvaldehyde Oxoquinolines use Quinolones Oxosteroids use Ketosteroids Oxosuccinates use Oxaloacetates ...
Oxopropanal use Pyruvaldehyde Oxoquinolines use Quinolones Oxosteroids use Ketosteroids Oxosuccinates use Oxaloacetates ...
Oxopropanal use Pyruvaldehyde Oxoquinolines use Quinolones Oxosteroids use Ketosteroids Oxosuccinates use Oxaloacetates ...
  • Reaction of guanine with glyoxal, pyruvaldehyde, and kethoxal, and the structure of the acylguanines. (wikipedia.org)
  • 4. Copper-62-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. (nih.gov)

No images available that match "pyruvaldehyde"